Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Bayer Pharma Aktiengesellschaft patents (2015 archive)


Recent patent applications related to Bayer Pharma Aktiengesellschaft. Bayer Pharma Aktiengesellschaft is listed as an Agent/Assignee. Note: Bayer Pharma Aktiengesellschaft may have other listings under different names/spellings. We're not affiliated with Bayer Pharma Aktiengesellschaft, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Bayer Pharma Aktiengesellschaft-related inventors


12/31/15 / #bet protein-inhibitory, especially brd2-, brd3- and brd4-inhibitory, 4-substituted pyrrolo- and pyrazolodiazepines of the general formula i

Bayer Pharma Aktiengesellschaft

. . ... Bayer Pharma Aktiengesellschaft

12/31/15 / #20150376189

Amidoimidazopyridazines as mknk-1 kinase inhibitors

The present invention relates to amido-substituted imidazopyridazine compounds of general formula (i): in which a, r1, r2, r3, r4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

12/24/15 / #20150368260

Amino-substituted isothiazoles

The present invention relates to isothiazoles of general formula (i) which inhibit the mitotic checkpoint: in which a, r1 and r2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

12/03/15 / #the present invention relates to bet protein-inhibitory, especially brd4-inhibitory, dihydroquinoxalinones of the general formula (i)

Bayer Pharma Aktiengesellschaft

. . ... Bayer Pharma Aktiengesellschaft

12/03/15 / #20150343099

Combination comprising radium-223 for the treatment of cancer

The present invention relates to combinations comprising compounds a and b, compound a being a 17α-hydroxylase/c17,20-lyase (cyp17) inhibitor, and compound b being a pharmaceutically acceptable salt of the alkaline-earth radionuclide radium-223 and their use for the treatment or prophylaxis of a disease, particularly for the treatment of cancer.. . ... Bayer Pharma Aktiengesellschaft

11/26/15 / #20150335822

Lock for drug injection device

A drug injection device comprises a main body case, a drug syringe mounting component, a piston, a drive mechanism, a controller, and means for locking the lid during operation of the drug injection device. The main body case has a lid and a base and an injection needle let-in/let-out opening. ... Bayer Pharma Aktiengesellschaft

11/26/15 / #20150335706

Formulation for bispecific t-cell engagers (bites)

The present invention relates to stable pharmaceutical compositions which contain polypeptides having at least two antigen-binding domains and are especially suited for subcutaneous administration. The invention provides liquid compositions which minimize the formation of undesired polypeptide aggregates (dimers and/or multimers). ... Bayer Pharma Aktiengesellschaft

11/19/15 / #20150329613

Fusion polypeptides and uses thereof

The present invention provides relaxin fusion polypeptides with extended half-life. Thereby, the half-life extending parts are either the fc moiety of the human igg2 or of the human igg4. ... Bayer Pharma Aktiengesellschaft

11/05/15 / #20150317908

Patient reported outcome instruments for endometriosis

The present invention relates to methods of diagnosing, treating, and monitoring endometriosis utilizing patient reported outcome instruments.. . ... Bayer Pharma Aktiengesellschaft

10/29/15 / #20150306102

Substituted pyrazolopyrimidines as akt kinase inhibitors

Compounds of formula (i) which are effective inhibitors of the pi3k/akt pathway, processes for their production and their use as pharmaceuticals.. . ... Bayer Pharma Aktiengesellschaft

10/22/15 / #the present invention relates to bet-protein-inhibitory, in particular brd4-inhibitory 5-aryltriazoloazepines of the general formula (i)

Bayer Pharma Aktiengesellschaft

. . ... Bayer Pharma Aktiengesellschaft

10/01/15 / #20150274719

Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use

The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

10/01/15 / #20150274695

N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group

The present invention relates to n-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i).. ... Bayer Pharma Aktiengesellschaft

10/01/15 / #20150274666

5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group

The present invention relates to 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i).. ... Bayer Pharma Aktiengesellschaft

09/24/15 / #20150267258

Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients

This invention is directed to the use of one or more biomarkers defined as kras or nras gene for predicting the pharmaceutical efficacy or clinical response of mek protein kinase inhibitor and/or sorafenib or regorafenib to be administered to a hepatocellular carcinoma (hcc) patient. Further the invention is directed to in-vitro methods for identifying mutated-type kras or nras gene in hcc patient and kits thereof.. ... Bayer Pharma Aktiengesellschaft

09/17/15 / #20150259300

4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group

The present invention relates to 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amine derivatives of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i).. ... Bayer Pharma Aktiengesellschaft

09/10/15 / #20150252047

Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases

The present invention relates to substituted indazol-pyrrolopyrimidine compounds of general formula (i): in which r1a, r1b, r1c, r1d, r2a and r2b are as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

08/27/15 / #20150239891

Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors

The present invention relates to substituted pyrrolopyrimidinylamino-benzothiazolone compounds of general formula i as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

08/06/15 / #20150218173

Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders

The present invention relates to substituted indazol-pyrrolopyrimidine compounds of general formula i: in which r1a, r1b, r1c, r1d, r2a are as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

07/30/15 / #20150210734

3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments

The invention relates to akr1c3 inhibitors and to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular bleeding disorders and endometriosis.. . ... Bayer Pharma Aktiengesellschaft

07/23/15 / #what is described are bet protein-inhibitory, in particular brd4-inhibitory 2,3-benzodiazepines of the general formula (i)

Bayer Pharma Aktiengesellschaft

. . ... Bayer Pharma Aktiengesellschaft

07/09/15 / #20150191431

N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products

The invention relates to n-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides, intermediates and methods for their production, use thereof for treating and/or preventing diseases and use thereof for producing medicinal products and use thereof for treating and/or preventing diseases, especially of hyperproliferative diseases.. . ... Bayer Pharma Aktiengesellschaft

07/02/15 / #20150183773

Substituted piperidines

The invention relates to novel substituted piperidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders and tumour disorders.. . ... Bayer Pharma Aktiengesellschaft

06/25/15 / #20150174113

Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof

The present application relates to novel substituted aminoindane- and aminotetralinecarboxylic acids, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of cardiovascular and cardiopulmonary diseases.. . ... Bayer Pharma Aktiengesellschaft

06/04/15 / #20150152121

Substituted benzothienopyrimidines

The present invention relates to substituted benzothienopyrimidine compounds of general formula i: in which r1a, r1b, r2a, r2b, and r2c are as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

06/04/15 / #20150152050

N-[3-(2-carboxyethyl)phenyl]piperidin-1-ylacetamide derivatives and use thereof as activators of soluble guanylate cyclase

The present application relates to novel substituted 2-(piperidin-1-yl)acetamide derivatives, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of cardiovascular diseases.. . ... Bayer Pharma Aktiengesellschaft

05/28/15 / #20150148542

Method for preparing substituted triazolopyridines

The present invention relates to methods of preparing substituted triazolopyridine compounds of general formula (i) as described and defined herein, as well as to intermediate compounds useful in the preparation of said compounds.. . ... Bayer Pharma Aktiengesellschaft

05/28/15 / #20150148376

Novel 5-aminotetrahydroquinoline-2-carboxylic acids and their use

The present application relates to novel 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular and cardiopulmonary disorders.. . ... Bayer Pharma Aktiengesellschaft

05/28/15 / #20150148340

Bicyclically substituted uracils and the use thereof

The present application relates to novel bicyclically substituted uracil derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases.. . ... Bayer Pharma Aktiengesellschaft

05/21/15 / #20150141372

Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer

Compounds of formula (i), processes for their production and their use as bub1 kinase inhibitors for the treatment of hyperproliferative diseases and/or disorders responsive to induction of cell death.. . ... Bayer Pharma Aktiengesellschaft

05/07/15 / #20150126449

(aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.. . ... Bayer Pharma Aktiengesellschaft

05/07/15 / #20150125527

Pharmaceutical administration forms comprising 5-chloro-n-(methyl)-2-thiophenecarboxamide

The present invention relates to solid orally administrable pharmaceutical administration forms comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide (rivaroxaban, active compound (i)), characterized in that a partial amount of the active compound (i) is released rapidly and a partial amount is released in a controlled manner (modified, retarded, delayed), and to processes for their preparation, their use as medicaments and their use for the prophylaxis, secondary prophylaxis or treatment of disorders.. . ... Bayer Pharma Aktiengesellschaft

04/30/15 / #the present invention describes intrauterine use of 18-methyl-15β,16β-methylene-19-nor-20-spirox-4-en-3-ones of the general formula (1)

Bayer Pharma Aktiengesellschaft

. . ... Bayer Pharma Aktiengesellschaft

04/16/15 / #20150104526

Substituted imidazopyridazines

The present invention relates to substituted imidazopyridazine compounds of general formula i in which r3, r5 and a are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

04/09/15 / #20150099298

Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof

The present invention relates to antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.. . ... Bayer Pharma Aktiengesellschaft

04/02/15 / #20150094300

Amino-substituted imidazopyridazines

The present invention relates to amino-substituted imidazopyridazine compounds of general formula (i); in which a, r1, r2, r3, r4, r5 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

03/19/15 / #20150080371

Substituted benzothienyl - pyrrolotriazines and uses thereof in the treatment cancer

This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-fj[1,2,4]triazin-4-amine derivatives having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.. . ... Bayer Pharma Aktiengesellschaft

03/05/15 / #the present invention describes intrauterine use of 18-methyl-15β,16β-methylene-19-nor-20-spirox-4-en-3-ones of the general formula (1)

Bayer Pharma Aktiengesellschaft

. . ... Bayer Pharma Aktiengesellschaft

01/01/15 / #20150005309

Substituted imidazopyrazines as akt kinase inhibitors

Compounds of formula (i) which are effective inhibitors of the pi3k/akt pathway, processes for their production and their use as pharmaceuticals.. . ... Bayer Pharma Aktiengesellschaft








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Bayer Pharma Aktiengesellschaft in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Bayer Pharma Aktiengesellschaft with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###